Meeder Asset Management Inc Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Meeder Asset Management Inc reduced its stake in Johnson & Johnson by 1.75% during the most recent quarter end. The investment management company now holds a total of 103,989 shares of Johnson & Johnson which is valued at $13,001,745 after selling 1,854 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Jul 22, 2016.Johnson & Johnson makes up approximately 1.18% of Meeder Asset Management Inc’s portfolio.

Other Hedge Funds, Including , Conestoga Capital Advisors reduced its stake in JNJ by selling 128 shares or 2.86% in the most recent quarter. The Hedge Fund company now holds 4,351 shares of JNJ which is valued at $544,006. Johnson & Johnson makes up approx 0.04% of Conestoga Capital Advisors’s portfolio.Nikko Asset Management Americas reduced its stake in JNJ by selling 1,900 shares or 12.1% in the most recent quarter. The Hedge Fund company now holds 13,800 shares of JNJ which is valued at $1,726,932. Johnson & Johnson makes up approx 0.16% of Nikko Asset Management Americas’s portfolio.Mitchell Mcleod Pugh Williams Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 700 additional shares and now holds a total of 15,614 shares of Johnson & Johnson which is valued at $1,922,708. Johnson & Johnson makes up approx 1.42% of Mitchell Mcleod Pugh Williams Inc’s portfolio.Lodestar Investment Counselil boosted its stake in JNJ in the latest quarter, The investment management firm added 490 additional shares and now holds a total of 227,049 shares of Johnson & Johnson which is valued at $27,958,814. Johnson & Johnson makes up approx 3.85% of Lodestar Investment Counselil’s portfolio.Quotient Investors reduced its stake in JNJ by selling 8,600 shares or 18.82% in the most recent quarter. The Hedge Fund company now holds 37,108 shares of JNJ which is valued at $4,564,284. Johnson & Johnson makes up approx 2.09% of Quotient Investors’s portfolio.

Johnson & Johnson opened for trading at $124.34 and hit $125.32 on the upside on Friday, eventually ending the session at $125.23, with a gain of 0.62% or 0.77 points. The heightened volatility saw the trading volume jump to 70,20,910 shares. Company has a market cap of $344,463 M.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Investors should note that on Jul 20, 2016, Johnson & Johnson announced a cash dividend of $0.2900. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Aug 19, 2016.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *